

ASX Announcement

Correction - CSIRO SARS-CoV-2 Antiviral Screening Program

Sydney Australia, 20 July 2020: Recce Pharmaceuticals Ltd (**ASX: RCE**) advises of a correction to its ASX Announcement issued on 8 July 2020 in relation to its acceptance into the SARS-CoV-2 Antiviral Screening Program collaboration between CSIRO and The Peter Doherty Institute for Infection and Immunology (**Doherty Institute**).

Whereas Recce has delivered two of its compounds to CSIRO, only RECCE[®] 327 has been accepted to the SARS-CoV-2 Antiviral Screening Program. RECCE[®] 529 has not at this time been assessed or accepted by CSIRO or the Doherty Institute.

The fee-for-service SARS-CoV-2 Antiviral Screening Program is being undertaken as a collaboration between CSIRO and the Doherty Institute. For avoidance of doubt, it is not being separately overseen or funded by the Australian Government. While Recce is delighted that one of its compounds has been accepted to the screening program, such acceptance is not an indication that the compound is safe or effective as a treatment of SARS-CoV-2.

This announcement has been approved for release by Recce Pharmaceuticals Board.



ASX: RCE

Head Office: Level 36, 1 Macquarie Place, Gateway Tower, SYDNEY NSW 2000 **T** +61 (02) 8075 4585 **F** +61 (02) 8075 4584

R&D Centre - Perth: Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9362 9860

Washington Office: 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA